Combining targeted therapies significantly boosted survival in kidney cancer study
Results of a phase 1/2 trial led by Roswell Park Comprehensive Cancer Center show that combining the targeted therapies bevacizumab (Avastin) and pazopanib (Votrient) significantly extends both progression-free and overall survival in patients with the most common type of kidney cancer. Saby George, M.D., FACP, professor of oncology in the Department of Medicine, is principal investigator of the…
Read original article on Medical Xpress - latest medical and health news stories →Related news
-
A Dermatologist Shares Her Secret to Preventing Dark Spots
Health
Medicine
-
Your bottom shape doesn't reveal your estrogen levels—despite what social media says
Health
Medicine
-
3 ways to find and nurture better friendships
Culture & Lifestyle
Relationships
-
Snake-inspired soft robot could help doctors diagnose and treat small intestine disorders
Science
Research
-
Health coverage more strongly associated with income than world region
Health
Public Health
Global
-
People in tune with their bodies pay a lower health price for politics, without switching off
Health
Mental Health
United States
-
Restoring an amino acid can diminish age-related inflammation
Health
Aging
-
Controlled inhalation of thin air may alleviate Parkinson's symptoms
Health
Medicine
Brazil